Hub and Spoke Gareth Jones Hub and Spoke What is in the DH Hub - - PowerPoint PPT Presentation

hub and spoke
SMART_READER_LITE
LIVE PREVIEW

Hub and Spoke Gareth Jones Hub and Spoke What is in the DH Hub - - PowerPoint PPT Presentation

Hub and Spoke Gareth Jones Hub and Spoke What is in the DH Hub and Spoke proposal? NPA Hub and Spoke T&F Group DH proposal Amend s10(1) of the Medicines Act 1968 Enable inter-company Hub and Spoke arrangements


slide-1
SLIDE 1

Hub and Spoke Gareth Jones

slide-2
SLIDE 2

Hub and Spoke

  • What is in the DH Hub and Spoke proposal?
  • NPA Hub and Spoke T&F Group
slide-3
SLIDE 3

DH proposal

  • Amend s10(1) of the

Medicines Act 1968

  • Enable inter-company

Hub and Spoke arrangements

  • “create a level playing

field”

slide-4
SLIDE 4

DH proposal

  • Part of the DH narrative
  • n efficiencies – referred

to repeatedly at recent Parliamentary meeting by the Minister and Chief Pharmaceutical Officer

slide-5
SLIDE 5

DH proposal – “impact assessment”

  • 45% of medicines will be

dispensed in hub and spoke arrangements within 3 years

  • 10% reduction in

pharmacist labour costs in spokes

slide-6
SLIDE 6

DH proposal – “impact assessment”

  • For every job lost in

the spoke, 0.4WTE will be created in the hub

slide-7
SLIDE 7

DH proposal – “impact assessment”

  • Capital investment costs

excluded from the calculations

slide-8
SLIDE 8

NPA Hub and Spoke T&F Group

  • Manchester University literature review
  • Over 400 members responded to survey
  • Visit to an automated hub
  • Interview 20 experts
  • Legal opinion from a QC
  • Members of group from NPA, PSNC and

PV

slide-9
SLIDE 9

Benefits

  • Capacity

– Some opportunity to support capacity release to deliver other services – No evidence that there are cash savings within pharmacies

slide-10
SLIDE 10

More efficient?

  • Can not reduce staffing in a typical

independent – you can redeploy capacity

  • Reducing staff can be counterproductive

and potentially less safe

  • Hub service fee
  • Replication of process

– Accuracy check in spoke – FMD check in spoke

slide-11
SLIDE 11

More efficient?

  • Ineligible lines
  • Barriers

– Lack of original pack dispensing – Low level of repeat dispensing

  • Reduce stock levels?
  • Resilience?
  • Can MDS packs be done within inter-

company Hub and Spoke?

slide-12
SLIDE 12

Safer?

  • Misleading to portray this as a case of

humans versus machines

  • Existing error rate is low
  • FMD authentication process may deliver

the safety benefit without automated dispensing

  • New opportunities for error
slide-13
SLIDE 13

Impact on competition & procurement

  • Risk of a duopoly due to barriers to entry

– DTP / restricted wholesaler schemes – Investment – Infrastructure

  • Risk to short-liners

– Reducing amount of business open to short- liners, challenge to reach critical mass

  • Risk to the tax-payer
slide-14
SLIDE 14

Barriers

  • EU Falsified Medicines Directive
  • Accuracy check requirement
  • DTP/limited wholesaler schemes
  • Lack of competition between hubs
slide-15
SLIDE 15

Enablers

  • Original pack dispensing
  • Electronic Repeat Dispensing
  • New service commitment, eg, Pharmacy

First

  • Public specification for hubs
slide-16
SLIDE 16

Enablers

  • Fair contractual arrangements
  • GPhC recognition of the additional risks

involved within inter-company hub and spoke

slide-17
SLIDE 17

Conclusion

  • The inter-company hub and spoke idea is

integral to the Ridge/Cavendish view of the world

  • DH document shows a complete lack of

understanding of the issues

  • This politically driven proposal, as

currently framed, can not deliver the promised level playing field

slide-18
SLIDE 18

Conclusion

  • DH needs to go back to the drawing board
  • Please respond to the consultation, which

closes on 17th May 2016